Frost & Sullivan: Pharmaceuticals, Biotechnology & Drug Discovery Technologies

To achieve continued double digit growth and mitigate risks in R&D and manufacturing, pharma companies must gather actionable intelligence that will enable them to move rapidly from quantity-based, fee-for-service model to outcomes based contracts and adopt new digital platforms to deliver targeted therapeutics and improve profitability in a transformed healthcare market.